SCHEMBL13899176

SCHEMBL13899176

O=c1c(-c2cccs2)c(N2CCNCC2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.44
ALDH1A1 P00352 9/20 0.42
CYP1A2 P05177 9/20 0.42
CYP3A4 P08684 9/20 0.42
MEN1 O00255 8/20 0.42
USP2 O75604 8/20 0.42
CASP1 P29466 8/20 0.42
CASP7 P55210 8/20 0.42
KMT2A Q03164 8/20 0.42
CYP2C9 P11712 7/20 0.42
HIF1A Q16665 7/20 0.42
HSD17B10 Q99714 6/20 0.42
FLT3 P36888 2/20 0.41
TP53 P04637 5/20 0.40
CLK4 Q9HAZ1 4/20 0.40
CYP2C19 P33261 4/20 0.40
HPGD P15428 4/20 0.40
LMNA P02545 3/20 0.40
CYP2D6 P10635 3/20 0.40
MAPK1 P28482 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10077099 0.74 HTR6 (0.49) ADRB1ALDH1A1USP2HSD17B10HPGD
SCHEMBL10077100 0.72 HTR2C (0.40) ADRB1ALDH1A1CYP1A2CYP3A4MEN1
SCHEMBL13118685 0.70 ADRB1 (0.52) ADRB1ALDH1A1CYP1A2CYP3A4USP2
SCHEMBL10078400 0.70 HRH1 (0.40) ADRB1CCNCCDK8
SCHEMBL4328483 0.68 ADRB1 (0.47) ADRB1ALDH1A1FLT3
SCHEMBL2868372 0.67 HTR7 (0.62) ADRB1ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL28340857 0.66 ADRB1 (0.45) ADRB1ALDH1A1FLT3
Hydrochloric Acid SCHEMBL2276826 0.66 ADRB1 (0.45) ADRB1ALDH1A1FLT3HPGDLMNA
SCHEMBL4676744 0.66 KCNH2 (0.59) ADRB1ALDH1A1CYP1A2CYP3A4MEN1
SCHEMBL3766149 0.65 FLT3 (0.54) ADRB1ALDH1A1CYP1A2CYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501419-B2 4-Squarylpiperazine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-10 US disclosed
US-7501419-B2 4-Squarylpiperazine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-10 US disclosed
WO-2007127731-A1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-08 WO disclosed
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents MAVS, MTAP, SAMHD1 ADRB1 3216/4885ALDH1A1 2043/4885CYP1A2 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.